A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2006
11/23/2006	US20060263809 Method for sensitive measure of low level apoptosis in cells
11/23/2006	US20060263776 Serine protease
11/23/2006	US20060263774 Nucleotide sequences, vectors, transformed host cells, polypeptides, antibodies; monocyte/macrophage mediated disorders
11/23/2006	US20060263770 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
11/23/2006	US20060263450 Method and composition for reducing body weight and improving control of body lipids
11/23/2006	US20060263433 Suspension formulation of interferon
11/23/2006	US20060263432 Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof
11/23/2006	US20060263430 instrument for inducing cytokine and method of inducing cytokine
11/23/2006	US20060263422 Pharmaceutical composition containing decoy and use of the same
11/23/2006	US20060263407 Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; stent implants
11/23/2006	US20060263392 Method for treating neovascularization
11/23/2006	US20060263391 Process for the preparation of hypoallergenic mosaic antigens
11/23/2006	US20060263386 Vaccines
11/23/2006	US20060263380 IL-12 as an adjuvant for Bordetella pertussis vaccines
11/23/2006	US20060263379 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host
11/23/2006	US20060263373 Utilization of an aminopeptidase inhibitor
11/23/2006	US20060263364 Mammalian chemokines; related reagents
11/23/2006	US20060263360 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
11/23/2006	US20060263359 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)
11/23/2006	US20060263355 Treatment of bone disorders
11/23/2006	US20060263351 Methods and compositions for protection against thrombolysis associated reperfusion injury
11/23/2006	US20060263348 Apolipoprotein l-i and/or derivated polypeptide for the treatment of and/or the prevention of diseases induced by trypanosoma
11/23/2006	US20060263347 Lyophilizing an aqueous mixture of a fibrinolytic metalloproteinase, a zinc stabilizer and optionally a bulking agent, in a citric acid or a water soluble citric acid salt buffer and reconstituing said lyophilized composition
11/23/2006	US20060263346 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds
11/23/2006	US20060263345 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
11/23/2006	US20060263344 Novel probiotic compositions and methods of using the same
11/23/2006	US20060263342 Peptides derived from a protein encoded by a polynucleotide overexpressed in human colon cancer cells; bladder, prostate and breast cancers; antimetastasis agents; diagnosis
11/23/2006	US20060263336 Cell targeting methods and compositions
11/23/2006	US20060263332 Therapies for brain tissue damage
11/23/2006	US20060263331 Therapeutic use of tumor necrosis factor-alpha mutein
11/23/2006	US20060263303 Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use
11/23/2006	US20060263302 Systemic oxygenation via gastric perfusion with perfluorocarbon (PFC)
11/23/2006	US20060263295 Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
11/23/2006	US20060263294 Tumor targeting agents and uses thereof
11/23/2006	US20060261014 Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
11/23/2006	DE19822711B4 Sensorsystem mit Portkörper Sensor system with port body
11/23/2006	DE102005055946A1 Cyclische Iminopeptid-Derivate Cyclic Iminopeptid derivatives
11/23/2006	DE102005023993A1 Nicht virales Vektorsystem zum Transport von Nukleinsäure in die Lunge Non-viral vector system for transporting nucleic acid into the lungs
11/23/2006	DE102005023761A1 An die Lck-SH3 und Hck-SH3 Domäne bindende Peptide At the Lck-SH3 and SH3 domain binding peptides Hck
11/23/2006	DE102005022319A1 Verwendung von Histonen zu therapeutischen Zwecken Use of histones for therapeutic purposes
11/23/2006	CA2609814A1 Method for amelioration of disease condition induced by mood disorder
11/23/2006	CA2608873A1 Single domain vhh antibodies against von willebrand factor
11/23/2006	CA2608747A1 Elastin producing fibroblast formulations and methods of using the same
11/23/2006	CA2608463A1 Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
11/23/2006	CA2608442A1 Psk- i and its modulators for the treatment/diagnosis of cancer
11/23/2006	CA2608376A1 Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
11/23/2006	CA2608332A1 Treatment of inflammatory bowel disease (ibd) with anti-angiogenic compounds
11/23/2006	CA2608198A1 Modulators of alpha-synuclein toxicity
11/23/2006	CA2608016A1 Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp
11/23/2006	CA2607291A1 Compositions and methods for modulating immune responses
11/23/2006	CA2607072A1 Materials and methods for regulating blood flow
11/23/2006	CA2606785A1 Fibroblast activation protein inhibitor compounds and methods
11/23/2006	CA2605508A1 Blockade of pin1 prevents cytokine production by activated immune cells
11/22/2006	EP1724354A2 Circular DNA molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy
11/22/2006	EP1724352A2 Specific nucleic acids and polypeptide from pathogenic strains of Neisseria
11/22/2006	EP1724351A2 Human Kallikrein-like genes
11/22/2006	EP1724350A1 Method and compositions for the diagnosis and treatment of cancer
11/22/2006	EP1724349A1 TIE Ligand Homologues
11/22/2006	EP1724346A2 Peptides binding to the Lck-SH3 and to the Hck-SH3 domain
11/22/2006	EP1724342A1 Process for producing erysipelothrix rhusiopathiae surface protective antigen mutant in escherichia coli
11/22/2006	EP1724339A1 Gene regulation therapy involving ferritin
11/22/2006	EP1724286A1 Variant CD44 polypeptide, polynucleotides encoding same, antibodies directed there against and method of using same for diagnosing and treating inflammatory diseases
11/22/2006	EP1724284A2 GLP-1 fusion proteins
11/22/2006	EP1724283A2 Corticotropin releasing factor receptor 2 agonists
11/22/2006	EP1724282A2 Method for the production of non-immunogenic proteins
11/22/2006	EP1724281A1 Pathogenic infection detection compositions and methods
11/22/2006	EP1724280A1 Use of peptides as penetrating cell carriers
11/22/2006	EP1724264A1 Nitriles and medicinal compositions containing the same as the active ingredient
11/22/2006	EP1723969A1 Granulocyte-macrophage colony-stimulating factor (GM-CSF) as remedy for nerve damages
11/22/2006	EP1723967A2 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
11/22/2006	EP1723962A1 Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
11/22/2006	EP1723961A2 Pharmaceutical composition comprising at least one bone morphogenetic protein (BMP)
11/22/2006	EP1723953A1 Nutritional supplements
11/22/2006	EP1723950A2 Method of treating dopaminergic gaba-nergic disorders
11/22/2006	EP1723855A1 gamma-polyglutamic acid (gamma-PGA, H Form) and gamma-polyglutamates for use as nutrition supplements in dietary products
11/22/2006	EP1723417A1 C20orf23 as modifier of the igfr pathway and methods of use
11/22/2006	EP1723415A1 Pdes as modifiers of the igfr pathway and methods of use
11/22/2006	EP1723251A2 In vitro test system for predicting patient tolerability of therapeutic agents
11/22/2006	EP1723247A1 Recombinant perforin, expression and uses thereof
11/22/2006	EP1723234A1 Vglut-specific dsrna compounds
11/22/2006	EP1723174A1 A novel modulator of glucocorticoid receptor activities
11/22/2006	EP1723172A1 Erythropoietin liquid formulation
11/22/2006	EP1723167A1 Novel phosphorylated sequences of phosphatase cdc25b, antibodies directed against said sequences and use thereof
11/22/2006	EP1723166A2 Materials and methods relating to the treatment of glioblastomas
11/22/2006	EP1723165A1 Identification of n-alkylglycine trimers for induction of apoptosis
11/22/2006	EP1723163A2 Isopeptide gap junction modulators
11/22/2006	EP1723139A1 Cell targeting conjugates
11/22/2006	EP1723124A1 Propenoyl hydrazides
11/22/2006	EP1722834A1 Matrix comprising naturally-occurring crosslinked protein backbone
11/22/2006	EP1722822A1 New complexes
11/22/2006	EP1722820A1 Long-acting solid formulation comprising triptorelin acetate
11/22/2006	EP1722819A2 Method for solubilising peptide mixtures
11/22/2006	EP1722813A1 Use of botulinum toxin for preparing a drug for preventing hair growth
11/22/2006	EP1722812A2 Liquefaction processes
11/22/2006	EP1722811A1 An agent for promoting induction of vascular differentiation, comprising hepatocyte growth factor
11/22/2006	EP1722810A1 Combination of morphogenic proteins having tissue inductive properties
11/22/2006	EP1722809A1 A differentiation- or regeneration-inducing agent for alveoli
11/22/2006	EP1722807A2 Methods for reducing oxidative damage
11/22/2006	EP1722801A1 Use of enhanced water to improve blood sugar management
11/22/2006	EP1722794A1 Methods and compositions for the treatment of conditions related to gastric acid secretion

1 ... 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 ... 3163